New journal hopes to capitalize on growing specialty pharmacy niche

Share this article:
New journal hopes to capitalize on growing specialty pharmacy niche
New journal hopes to capitalize on growing specialty pharmacy niche

Pharmacy Times launched a new title, Specialty Pharmacy Times, which will focus on policy, regulatory and legal issues, as well as product reviews, reimbursement and new clinical trends in specialty pharmacy.

“Current spending on specialty pharmaceuticals is estimated at more than $100 billion, with that figure expected to increase to $1.7 trillion in 2030," said Bill Schu, group editorial director, in an email. “Our audience needs to keep on top of key issues in the profession – clinical issues and issues from a practice and business point of view – and Specialty Pharmacy Times will fill that niche."

The journal's inaugural issue was unveiled at the Academy of Managed Care Pharmacy meeting in October, and copies will go out to qualified subscribers, gratis, said Tighe Blazier, president, Pharmacy Times. Qualified subscribers include corporate executives, reimbursement specialists and pharmacists, as well as pharmacy and formulary directors at managed care organizations and in government, among others.

Blazier said the journal hopes to attract pharmaceutical and biotech advertising clients that manufacture products and offer services that require specialized distribution channels. “They will be the main beneficiaries of this important new communication platform,” said Blazier. Specialty Pharmacy Times will also be supported by online advertising, and will begin sending out a bi-weekly e-newsletter “very soon,” per Blazier. An iPad version of the journal is also in the works.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.